| References: |
Brivanib is the hydrolyzed Form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of Brivanib (bms-540215) in water, the solubility of Brivanib (bms-540215) in DMSO, the solubility of Brivanib (bms-540215) in PBS buffer, the animal experiment（test） of Brivanib (bms-540215),the in vivo,in vitro and clinical trial test of Brivanib (bms-540215),the cell experiment（test） of Brivanib (bms-540215),the IC50, EC50 and Affinity of Brivanib (bms-540215), please contact DC Chemicals. |
-chemical-structure.gif)
